FCMV
IMVT icon

Foresite Capital Management V’s Immunovant IMVT Stock Holding History

Foresite Capital Management V’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$802K – 18
2021
Q1 		$802K Buy
+50,000
New +$1.32M 0.24% 20

Other funds holding IMVT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Foresite Capital Management V's IMVT Position: Q2 2021 in Review

Foresite Capital Management V sold out of Immunovant (IMVT) in Q2 2021, closing a stake of 50,000 shares — an estimated $802K sold.

Foresite Capital Management V first reported a position in IMVT in Q1 2021 and held it in 1 quarter. The position peaked at $802K in Q1 2021. 110 funds tracked by Wall St. Rank hold IMVT as of Q2 2021.

  • Foresite Capital Management V reported no remaining Immunovant position as of Q2 2021 after selling out during the quarter.
  • Foresite Capital Management V sold 50,000 Immunovant shares in Q2 2021, an estimated $802K.
  • Foresite Capital Management V first reported a position in Immunovant in Q1 2021 and held it in 1 quarter.
  • Foresite Capital Management V's Immunovant position peaked at $802K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held Immunovant as of Q2 2021.

Based on Foresite Capital Management V's 13F filing for Q2 2021, filed 16 Aug 2021.